May you introduce LSL Neurosciences
LSL Neurosciences is a biotech created in 2015 in the USA, specialized in research and development of drugs intended to fight neurodegenerative diseases, such as Alzheimer's disease.
Why did you found LSL Neurosciences?
I discovered and patented a line of research that seemed relevant to fight against Alzheimer's disease. After multiple researches and deepenings, the approval of KOL and the beginnings of very convincing proofs (phase 1 and 2, both positive), I realized the evidence, this track is very promising.
We had to move on to the development of the molecule.
What is your background?
I am a neuroscience researcher, I was (among other things) scientific advisor to a laboratory specializing in neurology and psychiatry.
My role was to help neurologists, psychiatrists and geriatricians in the fight against Alzheimer's disease. Training, conferences, research.
I have had the opportunity to meet with patients and families during the development of non-drug management programs.
I also intervened in the promotion of one of the drugs against this disease.
Where is your research?
As for our Alzheimer's program, we are no longer in research but in development. We are capitalizing on the originality and the advance that we have (10 years). Especially since more and more experts prove that we were right to favor this path as well as, unfortunately, the numerous failures of the other hypotheses.
Another fact, very encouraging for us: this morning (june 29) the FDA has just accepted a program in phase 2/3 which confirms the solidity of our hypothesis. This path is announced as a break in the fight against Alzheimer's. It is for us, to date, the only solution to lead to a disease modifyer drug, that is to say, capable of modifying the course of the disease and stopping it.
We are therefore more than ever confident and eager to continue our pre-clinical and clinical development. For this we will proceed to another fundraising.
How much do you need?
For this development we need $56M, spread over 5 years.
Why focus on Alzheimer's ?
Although we work on all neurodegenerative diseases, we focus our efforts on this pathology for two reasons: 1) because a real pandemic is coming. Every 3 seconds there is a new case of dementia in the world. Already today, everyone is directly or indirectly concerned. 2) we have the solution to stop this.
LSL Neurosciences is a biotech created in 2015 in the USA, specialized in research and development of drugs intended to fight neurodegenerative diseases, such as Alzheimer's disease.
Why did you found LSL Neurosciences?
I discovered and patented a line of research that seemed relevant to fight against Alzheimer's disease. After multiple researches and deepenings, the approval of KOL and the beginnings of very convincing proofs (phase 1 and 2, both positive), I realized the evidence, this track is very promising.
We had to move on to the development of the molecule.
What is your background?
I am a neuroscience researcher, I was (among other things) scientific advisor to a laboratory specializing in neurology and psychiatry.
My role was to help neurologists, psychiatrists and geriatricians in the fight against Alzheimer's disease. Training, conferences, research.
I have had the opportunity to meet with patients and families during the development of non-drug management programs.
I also intervened in the promotion of one of the drugs against this disease.
Where is your research?
As for our Alzheimer's program, we are no longer in research but in development. We are capitalizing on the originality and the advance that we have (10 years). Especially since more and more experts prove that we were right to favor this path as well as, unfortunately, the numerous failures of the other hypotheses.
Another fact, very encouraging for us: this morning (june 29) the FDA has just accepted a program in phase 2/3 which confirms the solidity of our hypothesis. This path is announced as a break in the fight against Alzheimer's. It is for us, to date, the only solution to lead to a disease modifyer drug, that is to say, capable of modifying the course of the disease and stopping it.
We are therefore more than ever confident and eager to continue our pre-clinical and clinical development. For this we will proceed to another fundraising.
How much do you need?
For this development we need $56M, spread over 5 years.
Why focus on Alzheimer's ?
Although we work on all neurodegenerative diseases, we focus our efforts on this pathology for two reasons: 1) because a real pandemic is coming. Every 3 seconds there is a new case of dementia in the world. Already today, everyone is directly or indirectly concerned. 2) we have the solution to stop this.
No Offer, Solicitation, Investment Advice, or Recommendations
This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by FINYEAR.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.
Finyear : Future of Finance Daily News
Chaineum : Blockchain Tech. Investment Bank
Chaineum IO : STO Platform, Tokenization Platform
HealthTech.Finance : Healthtech Investment Bank
Laurent Leloup : Blockchain & DeFi Advisor
Chaineum : Blockchain Tech. Investment Bank
Chaineum IO : STO Platform, Tokenization Platform
HealthTech.Finance : Healthtech Investment Bank
Laurent Leloup : Blockchain & DeFi Advisor
Autres articles
-
Tether investit dans StablR pour promouvoir l'adoption du stablecoin en Europe
-
Chainalysis acquiert Hexagate, fournisseur de solutions de sécurité WEB3
-
Nomination | Esker annonce la nomination de Dan Reeve en tant que membre du Comité Exécutif
-
Un montant de 1,8 million de dollars levé - La nouvelle ICO de Dogizen étonne les experts avec une approche inédite au monde
-
Shares Pro étoffe (déjà ?) son offre avec l'acquisition du PER compte-titres du groupe Inter Invest
Imprimer
Partager